AIDS gene therapy
The American company Sangamo BioSciences has announced the beginning of the first phase of clinical trials of the method of gene therapy for HIV infection. The drug under the working name SB-728-T blocks the work of the gene encoding the membrane receptor, the CCR5 protein, to which the human immunodeficiency virus attaches to penetrate the cell.
03.02.2009